Recently, international pharmaceutical giant Lilly launched the digital medical experience platform LillyDirect. Through third-party pharmacy dispensing services, patients can directly select various Lilly medicines, including weight loss pills, and deliver them to their doorstep. Boosted by this news, on January 4th local time, the stock price of Lilly rose to a historic high of $636.41 per share during trading.
Lilly launches a new platform
Directly reach consumers
Opening LillyDirect, a website launched by Lilly on January 4th, the reporter chose the disease "obesity" and had three experiences available: remote treatment, face-to-face doctor visits, and pharmacy services.
Selecting remote treatment will redirect the page to the website where the FORM project is located. The website introduces that the FORM project is customized by a specialized clinical team to provide users with a weight management plan. The reporter filled out an information collection questionnaire and submitted their weight loss demands, height and weight, medical history, and other information, but failed to pass the qualification certification for applying to join the FORM program. The reason is that the weight loss medical program is only applicable to BMI (Body Mass Index) ≥ 30kg/m; Sup2; Or BMI ≥ 27kg/m; Sup2; People with specific illnesses.
For patients who truly need it, FORM doctors can prescribe drugs that include GLP-1 drugs such as Zepbund from Lilly. Patients can also communicate with doctors through text messages or video chats.
Xia Mingde, chairman of Innohu Pharmaceutical, said in an interview that telemedicine played an important role during the COVID-19. In recent years, new medical technologies have been increasingly applied in the United States, and Lilly's model is a practice of innovative ecology.
In addition to obesity, patients with diabetes and migraine can also enjoy the nursing services provided by LillyDirect. Patients can access three types of services: telemedicine, seeking face-to-face doctors for diagnosis and treatment, and exploring pharmacy services. In addition, the website also provides basic disease science popularization content, presented in the form of text or video.
Patients can use this website to find nearby doctors. By selecting the corresponding disease, insurance coverage, location, and distance range, you can find the address and phone number of the matching physician. LillyDirect is open to US residents aged 18 and above.
Weight loss pills can be delivered to your doorstep
Lilly's ability to deliver weight loss pills and other medications to your doorstep is also one of the highlights of the LillyDirect website.
Patients can purchase the necessary medication through this website. Firstly, confirm that the planned purchase of Lilly drugs is within the directory provided on the website. Then, contact your doctor and ask them to send your prescription to Lilly Direct Pharmaceutical Solutions. Lilly's pharmacy suppliers will communicate with patients to confirm receipt of their prescriptions and provide follow-up services.
Lilly's weight loss drug Zepbound is also listed in the drug catalog provided on the website. On November 8th local time, the multinational pharmaceutical company announced that Zepbound injection has been approved by the US Food and Drug Administration (FDA). The company stated in a statement that this is the first and only obesity treatment drug in its class that activates two hormone receptors, glucose dependent insulinotropic peptide (GIP) and glucagon like peptide-1 (GLP-1). Tilpodide injection is suitable for weight management in adults who are obese (BMI ≥ 30kg/m& sup2;) or overweight (BMI ≥ 27kg/m& sup2;) and have hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease and other weight related diseases.
This medicine has attracted a lot of attention since its launch. It is worth mentioning that its price is lower than that of similar drugs such as Wegovy from Novo Nordisk.
Lilly's stock price hit a new high on the same day
Boosted by news from the Lilly "New" platform, the highest intraday price of Lilly on January 4th was $636.41 per share, reaching a historic high.
Since 2023, Lilly's stock price has been soaring. As of the close on January 5th, Lilly's stock price was $618.55 per share, with a market value of $587.2 billion, approximately $114.7 billion higher than Novo Nordisk.
Novo Nordisk's market value has become the largest in Europe. On June 4, 2021, Novo Nordisk's weight loss drug Wegovy was approved by the FDA, and the company's market value has since skyrocketed. On September 1, 2023, its market value had surpassed LVMH (Mo ë t Hennessy Louis Vuitton Group), topping the European market value list. Recently, the company's stock price has continued to rise.
转播
